To investigate the periocular adverse reactions to omidenepag isopropyl (OMDI).
Non-randomized comparative clinical study.
We enrolled 100 patients (100 eyes) with primary open-angle glaucoma or ocular hypertension who received initial treatment with OMDI or tafluprost in only one eye for ≥6 months. Photographs of the eyelids were taken on the day of the participants’ visit after ≥6 months of prescription. Subsequently, three ophthalmologists individually determined the occurrence of eyelid pigmentation, eyelash growth, and deepening of the upper eyelid sulcus (DUES). Additionally, a questionnaire on the subjective symptoms was administered. Multivariate analysis of baseline data was performed to investigate the factors involved in adverse reactions.
The mean duration of drug administration was 10.2±3.8 and 10.8±4.1 months in the OMDI and tafluprost groups, respectively. The frequencies of eyelid pigmentation, eyelash growth, and DUES were 0.0%, 0.0%, and 2.0%, respectively, in the OMDI group, whereas the corresponding values in the tafluprost group were 4.0%, 32.0%, and 12.0%. The only significant difference was that the OMDI group showed fewer subjects with eyelash growth than in the tafluprost group (P<.0001). In the questionnaire, the subjective symptoms of eyelid pigmentation, eyelash growth, and DUES were 8.0%, 2.0%, and 4.0%, respectively, in the OMDI group, whereas the corresponding values in the tafluprost group were 12.0%, 40.0%, and 4.0%. Multivariate analysis revealed a correlation between the type of drug administered and these adverse reactions (P=.005, R=0.38).
The frequencies of periocular adverse reactions to OMDI, ranging from 0% to 2.0%, were lower than those to tafluprost.

Copyright © 2021. Published by Elsevier Inc.

Author